NCT07564557 Septum-guided Segmentectomy for Deep Early-stage Lung Cancer (SGS2512)
| NCT ID | NCT07564557 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai Chest Hospital |
| Condition | Non-small Cell Lung Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 89 participants |
| Start Date | 2026-04-01 |
| Primary Completion | 2031-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 89 participants in total. It began in 2026-04-01 with a primary completion date of 2031-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the safety and effectiveness of a specialized surgical technique called "Septum-guided Segmentectomy" for treating early-stage lung cancer located deep within the lung tissue.Standard surgery for lung cancer often involves removing an entire lung lobe (lobectomy), which can significantly reduce a patient's breathing capacity. For small tumors, removing only a segment of the lung (segmentectomy) can preserve more healthy tissue. However, for tumors located deep in the lung, traditional segmentectomy is technically challenging and risks leaving cancer cells behind.In this study, surgeons will use the natural anatomical boundaries-the intersegmental veins and their surrounding thin membranes (septa)-as a guide to precisely remove the target lung segment. This "septum-guided" approach aims to ensure the cancer is completely removed while maximizing the preservation of healthy lung function.Participants will be followed for 3 years after surgery to monitor for cancer recurrence and assess their long-term recovery.
Eligibility Criteria
Inclusion Criteria: * Age 18-80 years * Clinical stage IA (cT1a-bN0M0) * tumor diameter ≤ 2 cm * Pathological feature: Solid-dominant lesion (CTR \> 0.5) * Tumor location: Deep-seated within the lung parenchyma (inner 2/3), defined as the tumor center being located in the inner 2/3 region of the lung field on axial, coronal, and sagittal CT views * ECOG Performance Status: 0-1 * Pulmonary function: FEV1 ≥ 60% predicted and DLCO SB ≥ 60% predicted * Participants must be willing and able to provide written informed consent Exclusion Criteria: * Multiple pulmonary nodules or evidence of distant metastasis * Intraoperative confirmation of lymph node metastasis (N1/N2) or pleural dissemination * History of previous ipsilateral lung surgery * History of other malignant tumors within the past 5 years * Presence of severe cardiovascular or cerebrovascular diseases that preclude surgical tolerance * Pregnancy or breastfeeding
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07564557 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Non-small Cell Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07564557 currently recruiting?
Yes, NCT07564557 is actively recruiting participants. Contact the research team at drgengjunfeng@163.com for enrollment information.
Where is the NCT07564557 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT07564557 clinical trial?
NCT07564557 is sponsored by Shanghai Chest Hospital. The trial plans to enroll 89 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.